YSI Webinar: Asymmetric power in the transnational innovation networks of B

Dear All,

Hope you are adapting to and making the best out of the current situation.

We want to invite you all to the third presentation of the webinar series on the Blurred frontiers b/w states and markets for pharmaceutical technologies. Our speaker Cecilia Rikap will discuss the role of asymmetric power in knowledge production by the Big Pharma and point out impacts of this pre-existing scenario for handling the pandemic.

Please do not hesitate to reach us if you have any troubles in joining the event and thank you for spreading the word.

More practical information is below.

Best Wishes,
Sauman & Cecilia

YSI Webinar: Asymmetric power in the transnational innovation networks of Big Pharma

This article theoretically and empirically analyzes leader corporations’ innovation processes in contemporary capitalism. We highlight three characteristics: their transnational scope, the primacy of power or asymmetric relations exercised by leaders over the participants of their innovation circuits or networks, and the relevance of what we called technological competition and technological cooperation between leaders. Focusing on the latter, our theoretical contribution integrates the concepts of innovation circuit, global innovation network and modularity of knowledge production in order to elaborate a preliminary model for synthesizing leader’s technological competition and collaboration behaviours. This model is the general framework used for studying three big pharma’s innovation networks (Roche, Novartis and Pfizer). In particular, we study those networks by considering two outputs: scientific publications and patents. Network maps are constructed based on institutions’ co-occurrences, thus looking at who is co-authoring their publications and co-owning these corporations’ patents. We find that big pharmaceuticals co-produce together mainly generic knowledge modules, thus develop strong technological cooperation. Simultaneously, to succeed in their technological competition they outsource stages of their innovation networks to subordinate institutions that, even if they contribute to achieving the innovation, will not be co-owners of the resulting patents, while big pharmaceuticals enjoy associated innovation rents.

Join us for a Webinar!
Join from PC, Mac, Linux, iOS or Android:
Time: May 15, 2020, 15:45 (Timezone: Asia/Calcutta)/ 12:15 (Timewone: CET)
Join from PC, Mac, Linux, iOS or Android: https://ysi.ineteconomics.org/project/5e32c399a953855d12fd91dc/event/5e42d7cfaf8e9a25bd3b3bc5
NOTE: If you can not join through the above link then please confirm your participation by replying to this email, and we will share the Zoom link with you about an hour before the webinar.